Zhang Ying, Kurupati Raj, Liu Ling, Zhou Xiang Yang, Zhang Gao, Hudaihed Abeer, Filisio Flavia, Giles-Davis Wynetta, Xu Xiaowei, Karakousis Giorgos C, Schuchter Lynn M, Xu Wei, Amaravadi Ravi, Xiao Min, Sadek Norah, Krepler Clemens, Herlyn Meenhard, Freeman Gordon J, Rabinowitz Joshua D, Ertl Hildegund C J
Gene Therapy and Vaccines Program, University of Pennsylvania (U of PA), Philadelphia, PA 19104, USA; The Wistar Institute, Philadelphia, PA 19104, USA.
The Wistar Institute, Philadelphia, PA 19104, USA.
Cancer Cell. 2017 Sep 11;32(3):377-391.e9. doi: 10.1016/j.ccell.2017.08.004.
How tumor-infiltrating T lymphocytes (TILs) adapt to the metabolic constrains within the tumor microenvironment (TME) and to what degree this affects their ability to combat tumor progression remain poorly understood. Using mouse melanoma models, we report that CD8 TILs enhance peroxisome proliferator-activated receptor (PPAR)-α signaling and catabolism of fatty acids (FAs) when simultaneously subjected to hypoglycemia and hypoxia. This metabolic switch partially preserves CD8 TILs' effector functions, although co-inhibitor expression increases during tumor progression regardless of CD8 TILs' antigen specificity. Further promoting FA catabolism improves the CD8 TILs' ability to slow tumor progression. PD-1 blockade delays tumor growth without changing TIL metabolism or functions. It synergizes with metabolic reprogramming of T cells to achieve superior antitumor efficacy and even complete cures.
肿瘤浸润性T淋巴细胞(TILs)如何适应肿瘤微环境(TME)中的代谢限制以及这在多大程度上影响其对抗肿瘤进展的能力仍知之甚少。利用小鼠黑色素瘤模型,我们报告称,当同时受到低血糖和低氧影响时,CD8 TILs会增强过氧化物酶体增殖物激活受体(PPAR)-α信号传导以及脂肪酸(FAs)的分解代谢。这种代谢转换部分保留了CD8 TILs的效应功能,尽管在肿瘤进展过程中,无论CD8 TILs的抗原特异性如何,共抑制因子的表达都会增加。进一步促进脂肪酸分解代谢可提高CD8 TILs减缓肿瘤进展的能力。程序性死亡受体1(PD-1)阻断可延缓肿瘤生长,而不改变TIL的代谢或功能。它与T细胞的代谢重编程协同作用,以实现卓越的抗肿瘤疗效,甚至实现完全治愈。